The historical rank and industry rank for Biocon's OCF Margin % or its related term are showing as below:
NSE:BIOCON'
s OCF Margin % Range Over the Past 10 Years
Min: 11.88 Med: 16.79 Max: 26.98
Current: 11.85
During the past 13 years, the highest OCF Margin % of Biocon was 26.98%. The lowest was 11.88%. And the median was 16.79%.
NSE:BIOCON's OCF Margin % is ranked better than 77.29% of 951
companies
in the Biotechnology industry
Industry Median: -64.23
vs NSE:BIOCON: 11.85
Biocon OCF Margin % Related Terms
Biocon OCF Margin % Historical Data
* Premium members only.
The historical data trend for Biocon's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BIOCON vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Biocon's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocon OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biocon's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Biocon's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocon (NSE:BIOCON) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biocon and its competitors. Over the past decade, Biocon's OCF Margin % has ranged from 11.88 to 26.98. According to the industry distribution chart, Biocon ranks #216 out of 951 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Biocon's OCF Margin % too high?
Biocon's current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 11.88 to a high of 26.98. Based on the distribution chart, Biocon ranks #216 out of 951 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Biocon has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocon ranks #216 out of 951 companies for OCF Margin %. This places Biocon in the top 23% of its industry — outperforming the majority of peers. Historically, Biocon's own OCF Margin % has ranged from 11.88 to 26.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biocon and its competitors. Biocon's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (NSE:BIOCON) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹339.70, compared to a current price of ₹426.80 — trading 25.6% above its estimated fair value. The current OCF Margin % is 0.00%. Biocon's overall GF Score™ is 89/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Biocon (NSE:BIOCON), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocon (NSE:BIOCON) Overvalued in 2026?
Based on GuruFocus' analysis, Biocon stock appears to be overvalued.
The current stock price of ₹426.80 is trading 25.6% above its estimated GF Value™ of ₹339.70.
GuruFocus considers Biocon to be Modestly Overvalued.
Key valuation signals for NSE:BIOCON:
OCF Margin %: 0.00%
GF Value™: ₹339.70 vs. price of ₹426.80 (25.6% above fair value)
No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
89GF Score
Get the complete analysis for NSE:BIOCON
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOCON has been successfully added to your 
